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Mycobacterium ulcerans, the etiological agent of
Buruli ulcer, causes extensive skin lesions, which
despite their severity are not accompanied by
pain. It was previously thought that this remarkable
analgesia is ensured by direct nerve cell destruc-
tion. We demonstrate here that M. ulcerans-
induced hypoesthesia is instead achieved through
a specific neurological pathway triggered by the
secreted mycobacterial polyketide mycolactone.
We decipher this pathway at the molecular level,
showing that mycolactone elicits signaling through
type 2 angiotensin II receptors (AT2Rs), leading to
potassium-dependent hyperpolarization of neurons.
We further validate the physiological relevance of
this mechanism with in vivo studies of pain sensi-
tivity in mice infected with M. ulcerans, following
the disruption of the identified pathway. Our find-
ings shed new light on molecular mechanisms
evolved by natural systems for the induction of
very effective analgesia, opening up the prospect
of new families of analgesics derived from such
systems.INTRODUCTION
Mycobacterium ulcerans is the causative agent of Buruli ulcer.
The incidence of BU is increasing worldwide, ranking third
among mycobacterial diseases (Sizaire et al., 2006; Wans-
brough-Jones and Phillips, 2006). In most cases, M. ulcerans
infection is associated with a subcutaneous nodule that is typi-
cally painless (Asiedu et al., 2000; Johnson et al., 2005). If un-
treated, the disease progresses to necrotic lesions and open
wounds, for which, ultimately, the only solution is heavy surgical
intervention. The absence of pain in the lesions, in the early infec-
tion stages, often results in delayed care seeking. Elucidation of
the precise mechanisms of hypoesthesia in Buruli ulcer is of
great importance, not only for prophylactic purposes but also
to improve our fundamental understanding of the modes of ac-
tion of natural analgesics.
It was thought until now that analgesia in Buruli ulcer is
achieved by direct destruction of nerve bundles, in particular
through the action of mycolactone (En et al., 2008; Goto et al.,
2006), a polyketide toxin secreted by M. ulcerans which is
essential for bacterial virulence, immune modulation, and host
colonization (Coutanceau et al., 2005; George et al., 1999; Gue-
nin-Mace´ et al., 2011; Marsollier et al., 2005; Marsollier et al.,
2007; Simmonds et al., 2009; Torrado et al., 2010). However,
several pieces of evidence contradict the hypothesis attributing
hypoesthesia induced by M. ulcerans to nerve degeneration. AsCell 157, 1565–1576, June 19, 2014 ª2014 Elsevier Inc. 1565
amatter of fact, nerve damage is observed only in the late stages
of infection, whereas painlessness usually occurs in the early
stages (En et al., 2008; Goto et al., 2006). Here, we seek to eluci-
date the mechanisms underlying the very effective induction of
analgesia in Buruli ulcer. We first reassess in detail the
hypothesis of nerve degeneration using a mouse model of
M. ulcerans infection. We show in this model that the induction
of analgesia by mycolactone is not accompanied by nerve
degeneration. Rather mycolactone induces cell hyperpolar-
ization, which we show is triggered by the angiotensin II receptor
(AT2R). We further dissect the underlying pathway showing that
mycolactone signaling involves cyclooxygenase 1 (COX-1) and
prostaglandin E2, resulting in the activation of TRAAK potassium
channels. Foremost, we validate in vivo the relevance of this
signaling pathway in the mycolactone-mediated hypoesthesia
induced byM. ulcerans, showing that blockade of AT2R restores
sensitivity to pain in mice.
RESULTS
M. ulcerans Induces Hypoesthesia in Early Stages of
Edema
We developed a mouse model to assess the relationship be-
tween hypoesthesia and nerve degeneration under low dose
conditions of M. ulcerans infection. M. ulcerans was injected
into the footpads of mice, and hypoesthesia was monitored
with the pain receptive tail-flick assay at different time points.
Under such conditions, mice exhibited redness at day 35 postin-
fection and edema at day 45. At both time points, hypoesthesia
was observed inM. ulcerans-infected animals, with a significant
tail-flick latency of 4 s, as compared to noninfected controls (Fig-
ure 1A). Histological analysis of mice inoculated withM. ulcerans
expressing GFP showed the presence of bacilli around the inoc-
ulation site, both in the stages of redness and edema (Figure 1B).
On the other hand, no GFP bacilli were found in nervous tissue,
either in glial cells or in axons. Macroscopic and ultrastructural
inspection revealed no signs of nerve degeneration (Figures 1C
and 1D). Similarly, extensive examination of more than 480 Re-
mak fibers showed no differences betweenM. ulcerans-infected
footpads and noninfected controls at the level of cytoskeletal cell
composition, organization of microtubules and filaments, struc-
ture of unmyelinated axons, or size of Schwann cell nuclei (Fig-
ures 1C and 1D). Finally, no obvious anomalies were observed
in the infected footpads at the level of myelinated or C-fibers
involved in sensory information transmission (Besson, 1999;
Griffin and Thompson, 2008). Taken together, these results
demonstrate that hypoesthesia in M. ulcerans infection is not
attributable to nerve degeneration, at least in this mouse model.
We next investigated the effect of direct inoculation of purified
mycolactone on hypoesthesia and nerve damage. Used as
control, lidocaı¨ne induced a transient hypoesthesia in our model
shortly after injection. Low doses of mycolactone produced
sustained analgesia for up to 2 days (Figure 1E). Noticeably,
nociceptive abilities were recovered after 8 days. Under these
conditions, as for M. ulcerans-infected samples, we performed
a close inspection of Remak fibers observing again that the
Schwann cells were intact (Besson, 1999; Hoeijmakers et al.,
2012). Thus, mycolactone injection alone is sufficient to produce1566 Cell 157, 1565–1576, June 19, 2014 ª2014 Elsevier Inc.hypoesthesia without nerve damage. Further, we also tested
chemically synthesized mycolactone, to rule out possible effects
of contaminants in our preparation of purified mycolactone. The
synthetic mycolactone induced the same level of reversible
hypoesthesia as the purified toxin, with the same concentrations
and application durations. This result clearly demonstrates that
the observed analgesic effect is attributable to the mycolactone
toxin (Figure 1E).
Mycolactone Induces Hyperpolarization of Neurons
With this hypothesis of nerve degeneration to account for hypo-
esthesia ruled out, it was natural to ask whether mycolactone
could instead produce hypoesthesia by interfering with relevant
neural transmission pathways. To this end, we examined the
effect of mycolactone onmembrane potential in neurons derived
from PC12 cells using the patch-clamp technique in the current-
clamp mode. Upon local and continuous application, mycolac-
tone induced a slowly developing cell hyperpolarization. As
compared to vehicle-treated neurons, an average decrease of
10 mV in the membrane potential was observed after 20 min
of incubation with purified mycolactone at subtoxic doses (Fig-
ures 2A, 2B, and Figure S1 available online). The same mem-
brane potential change was also observed with the synthetic
mycolactone, at the same concentration. After removal of the
toxin, the cells recovered their resting membrane potential, dis-
playing signal intensities similar to those before addition of toxin.
As amatter of fact, such reversibility of the effect of mycolactone
also supports the conclusion relative to the absence of neuronal
damage (Figure 2C). For enhanced characterization, we next
developed an image-based phenotypic assay based on the
monitoring of mycolactone-induced hyperpolarization. More
specifically, neurons were loadedwith the voltage-sensitive fluo-
rescent bis-oxonol probe DiSBAC2(3) (Dall’Asta et al., 1997) and
exposed to mycolactone. In this assay, the cell fluorescence
decreased within 20 min (Figure 2C), with the cells exhibiting
the same type of slowly developed hyperpolarization as that
observed by electrophysiological recordings of membrane po-
tentials. Accordingly we decided to monitor the effect of toxin
at 20 min in the following experiments. For image-based quanti-
fication of the samples, the DiSBAC2(3) signal was recorded
before addition of toxin and 20 min after ([T1int] and [T2int],
respectively), and the intensity ratio [T2int/T1int] was calculated
(Figures S2A and S2B). Such quantification of the samples
showed that 40% of the signal intensity was lost in the presence
of 0.175 ng/ml mycolactone (Figure 2D). Hyperpolarization is
typically associated with K+ channels, and we checked that
such channels were involved in themycolactone-induced hyper-
polarization. To this end we treated cells with the two K+ channel
blockers tetraethylammonium (TEA) and barium chloride (BaCl2).
As shown in Figures 2E and 2F, TEA andBaCl2 abolished themy-
colactone-mediated hyperpolarization demonstrating that it is
mediated by K+ efflux. At this level, the analgesic action of my-
colactone appears to share common features with the nonopioid
analgesic flupirtine, which also hyperpolarizes neurons by acti-
vation of K+ channels (Szelenyi, 2013). Furthermore, the K+
channels involved in the mycolactone-mediated hyperpolar-
ization appear to be sensitive to TEA and BaCl2 only at relatively
high concentrations (above 10 mM and 1 mM, respectively),
Figure 1. Absence of Pain in Buruli Ulcer Lesions Results from a Direct Anesthetic Effect of Mycolactone
(A) The nociceptive reflexwas quantified using a tail-flick unit. Mice infectedwithM. ulcerans (Mu) showed redness at day 35 and edema at day 45. NI: noninfected
group (n = 5 redness stage mice, n = 5 edema mice). Mean ± SD, ***p < 0.0001, Student’s t test.
(B) Histological analysis of cutaneous tissue from the footpad inoculated with M. ulcerans-GFP (green). Blue, DAPI; red, b3 tubulin staining with Texas red-
conjugated anti-b3 tubulin antibody. Representative image from a set of slides of tissues from fivemice (30 slides per tissue) that were analyzed at days 35 and 45
after M. ulcerans-GFP inoculation. Scale bars, 100 mm. Inset: Picture of the corresponding mouse footpad.
(C and D) Observation at the optical microscope (C) and ultrastructural (D) (electron microscope) levels of sciatic nerves innervating the infected (left) and
noninfected (right) footpads of animals at either the redness or the edema stage of injury. The black dotted line circumscribes a Remak bundle. Ax, axon; Mi,
mitochondria; Sch N, Schwann cell nucleus; Mt, microtubule; Mf, microfilament; My, myelin; CF, C-Fiber; SLI, Schmidt-Lanterman incisures. Scale bars, 40 mm
(C), and 5 mm (D).
(E) The nociceptive reflex was measured in mice after injection of 5 mg of purified mycolactone (black bars), synthetic mycolactone (hatched bars), lidocaine and
prilocaine anesthetics (gray bars), or absolute ethanol alone (vehicle control) (white bars). Mean ± SEM.
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Figure 2. Mycolactone Provokes Hyperpolarization via K+ Channels in Murine Primary Neurons
(A) Representative chart recordings of the membrane potential of PC12 cells challenged either by ethanol (vehicle), purified mycolactone or synthetic
mycolactone.
(B) Pooled data illustrating a 10mV-hyperpolarization triggered by continuous application of purifiedmycolactone or syntheticmycolactone for 10–20min. Dotted
line: mean.
(C) Photomicrographs of hippocampal neurons loaded with bis-oxonol (DiSBAC2(3)) and inoculated with mycolactone at 350 ng/ml or with ethanol (vehicle) at
various times. Scale bars, 100 mm.
(D) Quantification of the fluorescence intensity expressed as the ratio of bis-oxonol (DiSBAC2(3)) signal intensity at 20 min (T2int) to that at 0 min (T1int).
Mean ± SD.
(E and F) Effect of two K+ channels blockers, tetraethylammonium (TEA) and barium chloride (BaCl2) on the cell hyperpolarization caused by mycolactone.
Mean ± SEM.
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suggesting that they belong to the K2P channel family (Noe¨l
et al., 2011; Sandoz et al., 2012).
Identification of AT2R as the Target Receptor for
Mycolactone Involved in Cell Hyperpolarization
To further elucidate the cellular and molecular mechanisms un-
derlying the action of mycolactone we seeked to identify its
target receptor involved in the K+-mediated hyperpolarization.
To this end, we adapted the assay above to the large-scale
screening of a siRNA library targeting 8,000 different host genes.
Macrophage-like cells of the Raw267.4 cell line were used in this
screening as they are efficiently silenced by siRNAs (Carralot
et al., 2009). We first checked that the effect of mycolactone
on hyperpolarization in Raw267.4 cells is the same as in neurons
(Figure S2). For the screening experiments cells were first incu-
bated with siRNA and then loaded with DiSBAC2(3) immediately
before the addition of mycolactone. A decreased intensity ratio
was observed after the addition of toxin to cells that had been
incubated with nontarget (scrambled) siRNAs (Figure S3). The
most significant hits (roughly 1% of the total) were selected
from the primary screen, leading to 34 siRNA-targeted genes
upon retesting. In this set, only three genes appeared to be asso-
ciated with receptors, namely il23r, icam1, and agtr2 (Table S1).
With this respect, it is noticeable that no genes encoding opioid
receptors, common target of analgesics, were found among the
most significant hits from the siRNA screen.Whereas ICAM1 and
IL23R, belonging respectively to the immunoglobulin and inter-
leukin receptor families, do not appear to be associated in
any—direct—known way with nociceptive pathways, the angio-
tensin II type 2 receptor (AGTR2 or AT2R) represented a favor-
able candidate to account for the observed analgesia effects.
This receptor has been reported recently, in a completely
different context, to be specifically involved in nociception in
the course of experiments testing the effects of the AT2R chem-
ical antagonist PD123,319 (Anand et al., 2013). Accordingly we
focused our subsequent investigations on AT2R receptors. First,
we checked that silencing AT2R led to a high ratio value compa-
rable to that of the scramble control in the absence of toxin (Fig-
ure 3A). We then proceeded to investigate in detail the potential
role of AT2R as amediator ofmycolactone-mediated hyperpolar-
ization, seeking to fully characterize and decipher the associated
pathway. As a first direct characterization, we showed that neu-
rons isolated from AT2R knockout (AT2R-KO) mice (Hein et al.,
1995) were not hyperpolarized upon addition of mycolactone,
with no observed decrease in DiSBAC2(3) signal (Figure 3B).
Furthermore, we assessed in vitro the binding affinity of the my-
colactone toxin to human AT2R, which displays 95% amino acid
sequence identity with murine AT2R. Binding affinity of mycolac-
tone to AT2R was determined in a radioligand competition assay
using the agonist [125I] CGP42,112A (Pelegrini-da-Silva et al.,
2005). Mycolactone was able to inhibit the AT2R agonist with
an IC50 value of 3 mg/ml (Figure 3C). We further analyzed the
expression of AT2R in our settings and found that AT2R was ex-
pressed in mouse footpad. In this assay, infection with
M. ulcerans did not change significantly the level of expression
of AT2R (Figure S4), showing that AT2R is not upregulated after
infection. To further pinpoint the causal role of mycolactone in
cell hyperpolarization via AT2R receptors we performed twoadditional assays. First we showed that the AT2R-selective
antagonist PD123,319 inhibits mycolactone-induced hyperpo-
larization in neuronal cells (Figure 3D). In addition, it is known
that AT2R is a G protein-coupled receptor, which couples selec-
tively to pertussis toxin (PTX)-sensitive Gia2 and Gia3 proteins
(Kang et al., 1994; Sumners and Gelband, 1998). Upon preincu-
bation of the cells with the G-ai inhibitor PTX (Figure 3E), we
showed that mycolactone-mediated hyperpolarization was
abolished, thus demonstrating that G-ai proteins are involved
in mycolactone-induced AT2R signaling. In conclusion, inhibi-
tion of mycolactone signaling in absence of AT2R was demon-
strated through three different approaches, relying on chemical
inhibition and genetic knockdown as well as genetic knockout.
We further checked whether mycolactone could also signal
through AT1R, as is the case for angiotensin II. As a matter of
fact mycolactone displayed binding affinity to the human AT1R
similar to that measured for AT2R (Figure S5). Accordingly, we
tested the effect of mycolactone in an AT1R functional assay
whereby cytosolic Ca2+ ion mobilization is measured in
HEK293 cells expressing AT1R. No effect of mycolactone was
observed in this assay, up to 20 mg/ml, showing that despite
its binding on the receptor mycolactone does not trigger AT1R
activation. Confirming this result, we showed that mycolactone
signaling was abolished in neurons from mice KO for AT2R
(Clere et al., 2010; Hein et al., 1995) not impaired for AT1R
expression, thus excluding a role for AT1R in mycolactone-
induced hyperpolarization.
AT2R Induces Cell Hyperpolarization via
Cyclooxygenase Pathway
To dissect the mycolactone-induced pathway at the molecular
level, we performed a series of additional analyses of our siRNA
data, complemented by the screening of a chemical library of
inhibitors with known targets. Based on the identification of the
AT2R target above, the rationale in this two-pass screening
approach was to reanalyse the siRNA data, with a significantly
relaxed threshold, in order to further identify relevant genes
involved in the underlying pathway seeking notably to bridge
the gap between the AT2R-input and K+ channels-output levels.
In this second-pass screening the analyses were conducted in
the light of information available in the literature, concerning
various alternative pathways associated with the activation of
AT2R. As a matter of fact, it was documented in the literature
that modulation of K+ currents by AT2R signaling can follow
several different intracellular pathways (Nouet and Nahmias,
2000). The primary reported pathway involves the protein
PTPN6-SHP1, which becomes phosphorylated upon AT2R acti-
vation (Bedecs et al., 1997). In our cellular model, it was possible
to exclude this pathway for AT2R-mediated signaling because
addition of mycolactone did not result in any notable variation
in the amount of phosphorylated SHP1 (Figure S6). Another
reported pathway for AT2R modulation of K+ currents involves
signaling through activation of phospholipase A2 (PLA2) and
release of arachidonic acid (AA) (Lauritzen et al., 2000). We
showed that the AT2R-mediated signaling of mycolactone is
consistent with this pathway. More precisely, we were able to
dissect in detail the triggering of this pathway by mycolactone
and to assess the effects of the enzymes involved in theCell 157, 1565–1576, June 19, 2014 ª2014 Elsevier Inc. 1569
Figure 3. AT2R is Targeted by Mycolactone
(A) Fluorescence ratio of Raw267.4 cells treated either with siRNA targeting AT2R or with scrambled siRNA, and further loaded with bis-oxonol (DiSBAC2(3))
before incubation with mycolactone. The ratio is normalized to that of the scrambled siRNA control. Mean ± SD.
(B) Fluorescence ratio of neurons from AT2R deficient (AT2R KO) or wild-type (WT) mice; the neurons were loaded with bis-oxonol (DiSBAC2(3)) before incubation
with mycolactone. Mean ± SD.
(legend continued on next page)
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biosynthesis andmetabolism of AA.We found thatmycolactone-
induced hyperpolarization was inhibited upon silencing of
several PLA2 homologs that mediate the release of AA from
membrane phospholipids (Figure 3F). Mycolactone signaling
was also impaired upon silencing of cox-1 (ptgs1), which con-
verts AA into prostaglandins (Fletcher et al., 2010) (Figure 3F).
We showed that inhibition of PTGS1 by the chemical inhibitors
FR122047 and Piroxicam abolished mycolactone-mediated
hyperpolarization (Figure 3G). As Piroxicam is a nonselective
COX inhibitor, we further wanted to investigate the possible
involvement of COX-2 in this pathway. Accordingly, we tested
COX-2 inhibition either by silencing the expression of ptgs2 or
by using COX-2 selective inhibitors (Dup-697 and NS398). In
both cases, we observed no effects in our assay, thus ruling
out a putative role of COX-2 signaling in our scheme.
Refined Characterization of the K+ Channels Subfamily
Beyond the detailed characterization of the molecular pathway
between AT2R-input and K+ channels-output, the second-pass
reanalysis of our siRNA primary screen further allowed refining
the characterization of the K+ channels in terms of subfamily
assignment. More precisely, such reanalysis allowed to pinpoint
two possible candidate subfamilies to which the potassium
channels involved in themycolactone-induced hyperpolarization
belong, namely KCNK4 (TRAAK) and KCNK13 (THIK1) from the
K2P channels family (Figure 3F). Channels from the K2P family
function as regulatory hubs for the generation of negative resting
membrane potentials and therefore they constitute appropriate
final targets of the signaling pathway involved in the mycolac-
tone-induced hyperpolarization. As high concentrations of either
barium or TEA reversed the mycolactone-induced hyperpolar-
ization, we wanted to investigate the ability of BaCl2 and TEA
to block the activity of TRAAK. We showed that TRAAK is sensi-
tive to TEA and BaCl2 with an IC50 of 7 ± 2 mM and 0.5 ± 0.1 mM,
respectively (Figure S7). These IC50 values are in good agree-
ment with the concentration that provokes an inhibition of the
mycolactone-induced hyperpolarization (Figures 2E and 2F).
Accordingly, we asked the question as to which mediator was
involved in TRAAK activation. Based on the evidence above con-
cerning the involvement of the cyclooxygenase pathway in the
AT2R-induced cell hyperpolarization, it was natural to consider
first a possible direct role for arachidonic acid, known to activate
TRAAK channels. However, we could rule out this possibility, as
PTGS1 inhibitors abolished mycolactone-induced hyperpolar-
ization. Accordingly, we reasoned that the mediator responsible
for the activation of TRAAK channels could correspond to one of
the metabolites of arachidonic acid. With this respect, the anal-(C) Competitive binding of mycolactone to human AT2R. Mean ± SD.
(D) Fluorescence ratio of neurons incubated with PD123,319, a selective inhibito
lactone. Mean ± SEM.
(E) Fluorescence ratio of neurons incubated with Ga inhibitor pertussis toxin (P
Mean ± SEM.
(F) Fluorescence ratios of Raw267.4 cells treated with various siRNAs or scram
mycolactone. The ratios are normalized to that of the scrambled siRNA control. P
encoding genes. Ptgs1, COX-1; Ptges2, prostaglandin E synthase 2; Kcnk4, pota
member 13. Mean ± SD.
(G) Fluorescence ratio of neurons incubated with FR122047, a selective inhibitor
(H) Current increase in inside-out patches containing TRAAK after application ofysis of our screen data identified only one relevant candidate,
namely the enzyme prostaglandin E synthase 2 (PTGES2) (Fig-
ure 3F). Application of PGE2, the synthesis of which is catalyzed
by ptges2, induced a 4.1 ± 0.8-fold increase of the TRAAK
current showing that release of potassium via TRAAK can be
mediated by PGE2 (Figure 3H). Altogether, these results are
consistent with a model in which the mycolactone-induced
pathway, via AT2R at the input level, results in an increased
activity of TRAAK potassium channels at the output level, with
the intermediate pathway as detailed above.
Blockade of the AT2R Signaling Cascade Results in
Inhibition of Hypoesthesia Caused by Mycolactone
Completing the rationale for this molecular characterization, we
further demonstrated its physiological relevance by investigating
in vivo the causal role of AT2R in hypoesthesia. We first verified
that AT2Rs are not expressed in neurons in our KO model
(Hein et al., 1995) (Figure 4A). When mycolactone was injected
into the footpads of AT2R KO mice, the animals exhibited unal-
tered pain sensitivity in the tail-flick test, with an average
response time of 8 s, which contrasted with a delayed response
by an average of 12 s in wild-type animals (Figure 4B). Thus,
AT2R expression is critical for the occurrence of mycolactone-
mediated hypoesthesia under physiological conditions. This
result was substantiated by the tail-flick test on wild-type and
AT2R-KO mice that presented nonulcerative lesions after infec-
tion with M. ulcerans (Figure 4C). In addition, upon treating
M. ulcerans-infected mice exhibiting edema with the selective
AT2R blocker PD123,319 or with piroxicam, an inhibitor of pros-
taglandin synthesis by PTGS1, we observed the same pain-sen-
sitive phenotype as in the AT2R-KO animals (Figures 4D and 4E).
Taken together our results demonstrate the pivotal role of AT2R
signaling cascade in Buruli ulcer induced hypoesthesia.
DISCUSSION
The focus of the work here is the molecular dissection of a
previously unanticipated infection strategy employed by a bac-
terium that uses the mycolactone toxin as an effective analgesic
to annul the pain of the lesions it causes. It was previously
believed that absence of pain in Buruli ulcer disease could be
attributed to nerve damage, caused by the action of the toxin
mycolactone secreted by M. ulcerans. Accordingly, we first
revisited this hypothesis to test it in detail. We demonstrated,
with purified as well as synthetic mycolactone, that the analgesic
effect of the toxin was not accompanied by nerve degeneration.
In addition, it is clear that M. ulcerans does not associate withr of AT2R and loaded with bis-oxonol (DiSBAC2(3)), before addition of myco-
TX) and loaded with bis-oxonol (DiSBAC2(3)) before addition of mycolactone.
bled siRNA and loaded with bis-oxonol DiSBAC2(3) before incubation with
la2g2f, Pla2g1br and Pla2g10 are members of three different groups of PLA2-
ssium channel subfamily K member 4; Kcnk13, potassium channel subfamily K
of Ptgs1, before addition of mycolactone. Mean ± SEM.
10 mM PGE2.
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Figure 4. M. ulcerans and Mycolactone-Mediated Hypoesthesia Impaired In Vivo Upon Blockade of the AT2R Signaling Cascade
(A) Detection of AT2R by Western blot in neurons of wild-type (WT) or AT2R-deficient mice (AT2R KO). PC12 cells, strongly expressing AT2R were used as a
positive control.
(B) The nociceptive reflex wasmeasured in AT2R-KO (gray bars) or wild-type (white bars) mice, which had been inoculated with 5 mg of mycolactone. Mean ± SD,
*p<0.05,**p<0.001,***p<0.0001, Student’s t test.
(C) The nociceptive reflex was measured in AT2R-KO (gray bars) or wild-type (white bars) mice, which had been inoculated with M. ulcerans. M. ulcerans : Mu,
Whiskers plot, ***p<0.0001, Student’s t test.
(D) The nociceptive reflex was measured in wild-type mice withM. ulcerans-induced nonulcerative lesions, subsequently treated with PD123,319 (white bars) or
water vehicle (gray bars). Whiskers plot, ***p<0.0001, Student’s t test.
(E) The nociceptive reflex was measured in wild-type mice with M. ulcerans-induced nonulcerative lesions, subsequently treated with piroxicam (white bars) or
gelosed water only (gray bars). Whiskers plot, ***p<0.0001, Student’s t test. M. ulcerans (Mu).nerve fibers, and it is most likely that the toxin reaches neurons
through diffusion. Indeed, we have previously shown that the
toxin mycolactone can be shuttled within vesicles in human
lesions (Marsollier et al., 2007). In this background we endeav-
ored to explore alternative mechanisms, other than nerve dam-
age, accounting for the analgesic effect of mycolactone. Instead,
we sought to investigate possible interference of the toxin with
neural processes which could be involved in pain perception
and we addressed the question of painlessness for early lesions
that are not yet necrotic. It is likely that the effect of mycolactone
on necrosis is relevant to yet another phenomenon (Guenin-
Mace´ et al., 2013; Sarfo et al., 2013).
At a global level, we first demonstrated with electrophysiology
that mycolactone, purified as well as synthetic, exerts a clear-cut
effect on membrane potential, inducing hyperpolarization of
neurons. Based on this result, we then deployed a coherent,
multifaceted approach, to unravel the detailed molecular
pathway underlying this effect. In this approach, we identified,
at the input level, AT2R receptor as the target of mycolactone.
We further confirmed this result by showing that mycolactone-
induced hyperpolarization is inhibited upon blocking AT2R
expression. Similarly, we showed that at the output level hyper-
polarization was mediated by K+ channels, and we further
refined this characterization showing the specific involvement1572 Cell 157, 1565–1576, June 19, 2014 ª2014 Elsevier Inc.of TRAAK potassium channels. In order to gain a complete
molecular picture of the effect of mycolactone, we further
dissected the intermediate pathway between the input and
output levels, showing that the intracellular pathway involved
(1) activation of phospholipase A2, (2) release of arachidonic
acid by COX-1 and (3) activation of TRAAK by PGE2. Finally, to
firmly validate these findings on physiological grounds, we
demonstrated the causal role in vivo of AT2R in hypoesthesia.
In a global context, it will be interesting in future studies to
consider in more detail several aspects of the pathway underly-
ing the hypoesthesia model above. Thus, concerning the binding
of mycolactone to AT2R, the observed difference between affin-
ities measured in vitro and quantifications in tissues (Figure S7)
can seem at first surprising. However, very little is known about
the stability and the metabolism of the toxin in vivo, with the pos-
sibility that metabolites derived from the toxin being active on
AT2R (Scherr et al., 2013). The investigation of such possibility
can then be of potential pharmaceutical relevance. With this
respect, it is also significant that a similar range of difference in
concentrations between in vitro binding and cellular activity as-
says was previously reported for mycolactone in a completely
different context (Guenin-Mace´ et al., 2013). Another intriguing
aspect in our hypoesthesia model concerns the involvement of
COX-1, whereas analgesic effect of NSAIDs was shown to be
Figure 5. Model of the Signaling Cascade triggered by Mycolactone
Upon binding to the AT2R receptor, coupled to Gai, mycolactone triggers a
signaling cascade leading to PLA2 activation and inducing the synthesis of
arachidonic acid. Arachidonic acid is then metabolized by COX-1 into PGE2,
leading to the opening of TRAAK channels. AA, arachidonic acid; PTGS1,
COX-1; PGE2, prostaglandin E2; TRAAK, potassium channel subfamily K
member 4.associated with the inhibition of COX-1. Such observations
clearly identify COX-1 as central, multifaceted, player in the con-
trol of pain. Of course it will be highly informative to determine
whether such different mechanisms could be associated with
different types of pain. Also COX-1 is known to mediate anti-
inflammatory effect in immune cells, raising the question whether
the AT2R-mediated analgesic effect could also involve other
immune cells. As a matter of fact, our demonstration here of
the effect of mycolactone on macrophages, again via AT2R, rai-
ses the possibility that the toxin acts as a multi-target weapon.
Even though the scope of the study here concerned neuron tar-
gets for hypoesthesia, future studies concerning macrophages
should identify the underlying effects (such as anti-inflammatory)
in the case of such targets.
Beyond themolecular and physiological characterizations, the
findings here can be cast in more general perspectives relevant
to the theme of counteracting pain on health-oriented grounds. It
is particularly significant to notice that the pathway dissected
here involves a natural effector that does not belong to the
different classes of analgesics of common use today, such as
paracetamol (or acetaminophen), opiate molecules such as
morphine, or nonsteroidal anti-inflammatory drugs (NSAID)
such as salicylates. Notably, because of series of, more or less
severe, secondary effects it is rather unanimously recognized
that new potent analgesics, showing less adverse effects, are
highly desirable. With this respect the perspective in connecting
the understanding of the implementation of analgesia in natural
systems, such as the one described here, to the rational devel-
opment of medical pain-killing products does not appear to be
unrealistic. Emerging, but as yet disparate, results of genetic
as well as pharmacological studies in humans and rodents point
toward the critical involvement of various components of the
pathway deciphered here in different steps of pain perception
and alleviation. Thus, it is highly significant that recent studies
aiming to identify rare genetic variants associated with pain
sensation precisely pinpointed angiotensin pathways as being
of critical importance in trait heritability for pain sensitivity(Williams et al., 2012). On the other hand AT2R receptors have
been pinpointed recently, in completely independent contexts,
as important potential targets for several synthetic analgesic
drugs. Thus, AT2R antagonist PD123,319 (also called EMA200)
was reported to be effective in a rat model of prostate cancer-
induced bone pain (Anand et al., 2013; Muralidharan et al.,
2014). This is further corroborated by the fact that other EMA
derivatives, EMA300 and EMA401, alleviate neuropathic pain
through AT2R (Rice et al., 2014; Smith et al., 2013).
It is then well possible that various such results may fit into a
coherent yet multifaceted model, inspired by the one developed
here (Figure 5), with the perspective of developing a rational
basis for the design and selection of efficient analgesic mole-
cules, directly inspired by natural ones. On more immediate
grounds and in terms of health policies, unmasking the patho-
genesis strategies of the M. ulcerans bacillus should contribute
to a more knowledgeable attitude toward the disease and
encourage patients to seek care in the early stages of infection.
EXPERIMENTAL PROCEDURES
Bacterium
M. ulcerans (strain no. 1615) was originally isolated from a skin biopsy of a
human patient from Malaysia (George et al., 1999) The recombinant
M. ulcerans-GFP bacterium (strain no. JKD8083) was derived from an Austra-
lian strain in which GFP expression is controlled by the mls SigA-like promoter
(Tobias et al., 2009).
Mycolactones
Mycolactones were purified from M. ulcerans (strain 1615) extracts as previ-
ously described (George et al., 1999). Mycolactone purity was estimated to
be better than 98%, based on HPLC profiles. Mycolactone was diluted to
4 mg/ml in absolute ethanol and stored in the dark in amber glass tubes. Syn-
thesis of mycolactone was described elsewhere (Gersbach et al., 2011; Scherr
et al., 2013). Synthetic mycolactone was diluted to 500 ng/ml.
Animal Experimentation
AT2R knockout mice were generated and provided by L. Hein (Hein et al.,
1995). Six-week-old female FV/BN wild-type (Charles River France, http://
www.criver.com/ico) and AT2R knockout (Hein et al., 1995) mice were main-
tained under conventional conditions in the animal house facility of the Centre
Hospitalier Universitaire, Angers, France (Agreement A 49 007 002), adhering
to the institution’s guidelines for animal husbandry.
Mouse Models
For inoculation withM. ulcerans, fiftymicrolitres of a suspension containing 53
104 bacteria were injected subcutaneously into the left footpads of mice. For
inoculation with mycolactone, five micrograms of mycolactone diluted in
10 ml of ethanol were injected subcutaneously into the left footpads of mice.
In controls, 10 ml of absolute ethanol alone were injected into the left footpads.
Pain Receptive Assay
The pain receptive assay was performed by adapting the tail-flick procedure,
using the tail-flick unit (UGO BASILE). The sensitivity of the tissue to a noxious
thermal stimulus was measured. The radiant heat stimulus was focused on the
left footpad. The assay was performed twice each week onmice that had been
previously anesthetized. This assay was validated by local application of Emla
analgesic cream containing 5% lidocaine/prilocaine (Astra Zeneca).
Immunochemistry
After sacrifice, footpads were removed, frozen in isopentane cooled to30C,
and stored at 80C. Frozen tissues were serially sectioned using a Leica
cryostat. Sections (12 mm) were fixed in cold methanol for 10 min and washed
three times in PBS before blocking at room temperature for 1 hr in BSA 5%.Cell 157, 1565–1576, June 19, 2014 ª2014 Elsevier Inc. 1573
Sections were incubated overnight with Texas red-conjugated anti-B3 tubulin
antibody (Sigma) diluted 1/200 in PBS with 5% BSA and then rinsed with PBS
(33 5 min). The preparations were counterstained with 3 mM 4’6-diamidino-2-
phenylindole (DAPI; Sigma) for 5 min and washed twice with PBS. Slides were
mounted with an antifading solution and observed with a confocal microscope
(LSM, Leica). Tissues from seven mice per stage were analyzed, with 50 slides
per mouse.
Mouse Sciatic Nerve Sections for Transmission Electron
Microscopy
After deep anesthesia, a perfusion with phosphate buffer was performed after
section of the femoral artery. Fixation of the tissue was then performed with a
second perfusion with 4% paraformaldehyde and 0.1% glutaraldehyde in
phosphate buffer fixation. The sciatic nerve was subsequently isolated by
dissection. The samples were fixed for 30 min in 0.1 M cacodylate buffer
(pH 7.2) containing 2.5% glutaraldehyde for 1 hr at 4C and left to stand for
12 hr at 20C in cacodylate buffer. Specimens were progressively dehydrated
and embedded in Araldite (Fluka). After dehydration, thin sections were
stained with uranyl acetate and Reynold’s lead citrate and then examined on
a JEOL 120 EX electron microscope.
Cell Culture
Macrophage cells (Raw264.7, ATCC TIB-71) were cultured in RPMI 1640
(Invitrogen) supplemented with 10% heat-inactivated fetal calf serum (Invitro-
gen). Pheochromocytoma cell 12 (PC12) cells were plated on collagen IV-
coated culture dishes in DMEM supplemented with 10% horse serum and
5% fetal bovine serum. After 6 days, differentiation to a neuronal phenotype
was induced by incubation in DMEM supplemented with 2% horse serum,
1% fetal bovine serum, and 100 ng/ml nerve growth factor (Invitrogen). The
culture medium was changed every two days until differentiation was com-
plete (6–7 days). Primary cultures of hippocampal neurons were prepared
from neonatal (P0 to P2) BALB/c and FVB/N mice according to an established
protocol (Banker and Cowan, 1977) with minor modifications.
Electrophysiology
The membrane potential of PC-12 cells was recorded using the whole-cell
configuration of the patch-clamp technique in the current-clamp mode. PC-
12 cells were grown for 7 days on glass coverslips before being harvested.
After an overnight incubation, the glass coverslips were transferred into a
recording chamber and continuously superfused with Ringer’s saline buffer
containing 125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1.25 mM
NaH2PO4, 26 mM NaHCO3, 12 mM glucose, buffered to pH 7.4, at 30–32
C
and bubbled with 95% O2 and 5% CO2. Recording pipettes (3–5 MU resis-
tance) were filled with 140 mM potassium gluconate, 5 mM KCl, 2 mM
MgCl2, 1.1 mM EGTA, 5 mM HEPES, 4 mM MgATP, 0.3 mM NaGTP and
titrated to pH 7.2 with KOH. Membrane potential changes were monitored
using an EPC10 quadro USB patch-clamp amplifier and PATCHMASTER soft-
ware (HEKA Electronik, Germany). Signals were sampled at 10 Hz, filtered at
3 kHz and analyzed with FITMASTER software (HEKA Electronik). Cells were
current-clamped close to their resting potential (55 to 65 mV in average).
Membrane potential was continuously monitored for 10–20 min before and
10–20 min after mycolactone application at 1.4 mg/ml using a pneumatic
drug ejection system (PDES, npi electronic GmbH, Germany). Control cells
were stimulated with 2% ethanol as vehicle. For IC50 determinations for
TRAAK, defolliculated Xenopus oocytes were injected with 50 nl of cRNA at
0.02–0.4 mg/ml encoding mTRAAK and recorded 2–4 days later. For electro-
physiology, single oocytes were placed in a 0.3 ml perfusion chamber and
impaled with two standard microelectrodes (1–2.5 MU resistance) filled with
3 M KCl and voltage clamped with a Dagan CA-1 amplifier, in ND96 solution
(96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, 5 mM HEPES
[pH 7.4], with NaOH). Stimulation of the preparation, data acquisition, and
analysis were performed using pClamp software (Axon Instruments).
Cell-Based Fluorescence Assay, Image Acquisition by Automated
Confocal Microscopy and Data Analysis
Raw264.7 macrophages were harvested with Versene (GIBCO) and seeded at
a density of 104 cells per well in 384-well plates (Evotec, Hamburg, Germany) in1574 Cell 157, 1565–1576, June 19, 2014 ª2014 Elsevier Inc.50 ml RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum
(FCS) (all from Invitrogen). After overnight incubation, the medium was
removed, and the cells were labeled for 2 hr at 37C with bis-(1,3-diethylthio-
barbituric acid) trimethine oxonol (DiSBAC2(3), Invitrogen, B413) at 62.5 mg/ml.
The cells were thenwashed three timeswith imaging buffer containing 150mM
NaCl, 5 mM KCl, 10 mM HEPES, 2 mM CaCl2, 2 mM MgCl2, 5.5 mM glucose,
2.9 mM sucrose. A first series of image acquisition was conducted to ascertain
the proper labeling of the cells (T1int); mycolactone was then added to the
cells. After 20 min incubation at room temperature under mild shaking
(500 rpm), a second scan was performed to measure the intensity of the
fluorescence of the cells (T2int). Confocal images were recorded on an auto-
mated fluorescent confocal microscope Opera (Evotec) using a 203 water
objective (NA 0.70), 532 nm laser and 600 nm camera. Four fields per well
were recorded. Each image was then processed using dedicated in-house
image analysis software (IM). The image dynamics were checked through a
series of statistical tests (assessing notably average intensities and standard
deviations), designed to allow the removal of black or out-of-focus images.
DiSBAC2(3) staining was then segmented in the ‘‘DiSBAC stain’’ band using
an in-house method (Fenistein et al., 2008), and the ratio of the surface inten-
sity of the ‘‘DiSBAC stain’’ before and after mycolactone addition was deter-
mined for each well. This ratio is referred to as the Ratio [T2int/T1int].
Competitive Binding of Mycolactone to the Human AT2R
[125I]CGP 42,112A at 0.01 nM was used as agonist radioligand. Radioactivity
was detected by scintillation counting (Cerep Inc, Seattle, WA,
Assay Reference 0026). The radioligand was first incubated with membranes
from human recombinant HEK293 cells and the bound radioactivity
was measured. The membranes were then incubated with a high concen-
tration of angiotensin II (1 mM) and with [125I]CGP 42,112A radioactive ligand
to determine nonspecific binding of the ligand to the AT2R receptor. The radio-
ligand and the mycolactone (eight different concentrations) were incubated
with the cell membranes for 4 hr at 37C to determine the IC50 of the
mycolactone.
Chemical Reagents
Tetraethylammonium (TEA), an inhibitor of various potassium channels and
Piroxicam, a highly active inhibitor of prostaglandin were from Sigma. EMLA
cream containing 5% lidocaine and prilocaine anesthetics was from Astra
Zeneca. FR122047, a selective inhibitor of COX-1 signaling and PD123,319,
a selective inhibitor of AT2R signaling were from Tocris Bioscience. For the
mouse study, 200 ml (daily renewed) solution of piroxicam at 0.5 mg/ml in
1% gelosed water was administered by gavage every day starting 30 days
after M. ulcerans inoculation. Osmotic mini-pumps (AlzetVR model 2002,
Palo Alto, CA) containing PD123,319 were implanted subcutaneously under
anesthesia in the back of the neck of mice 30 days after M. ulcerans inocula-
tion, with a delivery rate of 20 mg/kg/day in water.
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